A share price of Rapport Therapeutics Inc [RAPP] is currently trading at $30.93, up 1.01%. An important factor to consider is whether the stock is rising or falling in short-term value. The RAPP shares have gain 7.85% over the last week, with a monthly amount glided 9.22%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Rapport Therapeutics Inc [NASDAQ: RAPP] stock has seen the most recent analyst activity on November 19, 2025, when BTIG Research initiated its Buy rating and assigned the stock a price target of $47. Previously, Truist started tracking the stock with Buy rating on September 16, 2025, and set its price target to $44. On August 06, 2025, H.C. Wainwright initiated with a Buy rating and assigned a price target of $31 on the stock. Citizens JMP started tracking the stock assigning a Mkt Outperform rating. TD Cowen initiated its recommendation with a Buy. Stifel started tracking with a Buy rating for this stock on July 02, 2024, and assigned it a price target of $35. In a note dated July 02, 2024, Jefferies initiated a Buy rating and provided a target price of $35 on this stock.
Rapport Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $6.43 and $42.27. Currently, Wall Street analysts expect the stock to reach $45 within the next 12 months. Rapport Therapeutics Inc [NASDAQ: RAPP] shares were valued at $30.93 at the most recent close of the market. An investor can expect a potential return of 45.49% based on the average RAPP price forecast.
Analyzing the RAPP fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.18, Equity is -0.29 and Total Capital is -0.21. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 30.15 points at the first support level, and at 29.38 for the second support level. However, for the 1st resistance point, the stock is sitting at 31.55, and for the 2nd resistance point, it is at 32.18.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Rapport Therapeutics Inc [NASDAQ:RAPP] is 36.37. On the other hand, the Quick Ratio is 36.37, and the Cash Ratio is 17.56.
Transactions by insiders
Recent insider trading involved Ceesay Abraham, Chief Executive Officer, that happened on Dec 17 ’25 when 5833.0 shares were sold. Chief Executive Officer, Ceesay Abraham completed a deal on Dec 17 ’25 to sell 5083.0 shares. Meanwhile, Director THE DOROTHY CEESAY IRREVOCABLE bought 15249.0 shares on Dec 17 ’25.
